Author + information
- Received August 23, 2006
- Revision received September 27, 2006
- Accepted November 28, 2006
- Published online February 20, 2007.
- ↵⁎Reprint requests and correspondence:
Prof. Gregory Y. H. Lip, University Department of Medicine, City Hospital, Birmingham B18 7QH, England.
The important role of the vascular endothelium in cardiovascular health is increasingly recognized. However, mature endothelial cells possess limited regenerative capacity. There is therefore much interest in circulating endothelial progenitor cells (EPCs) among the scientific community, especially into their purported role in maintenance of endothelial integrity and function, as well as postnatal neovascularization. It has been suggested that these cells might not only be responsible for the continuous recovery of the endothelium after injury/damage, but also might take part in angiogenesis, giving the hope of new treatment opportunities. Indeed, there is accumulating evidence showing reduced availability and impaired EPC function in the presence of both cardiovascular disease and associated comorbid risk factors. Thus, many studies into the potential for use of EPCs in the clinical setting are being undertaken. The goal of this review article is to provide an overview of data relevant to the clinical role of EPCs and perspectives for treatment of cardiovascular disorders.
↵1 Dr. Shantsila is funded by a research fellowship of the European Society of Cardiology.
We acknowledge the support of the Peel Medical Research Trust and the Research and Development Programme of the Sandwell and West Birmingham Hospitals NHS Trust for the Haemostasis, Thrombosis, and Vascular Biology Unit.
- Received August 23, 2006.
- Revision received September 27, 2006.
- Accepted November 28, 2006.
- American College of Cardiology Foundation
- Physiological factors and EPCs
- Cardiovascular risk factors and EPCs
- Diabetes mellitus
- Other risk factors
- EPCs and cardiovascular diseases
- Stable CAD
- Unstable CAD
- Heart failure
- Other disease states
- Effects of drug therapies on EPCs
- 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase inhibitors (statins)
- The renin-angiotensin-aldosterone system
- Miscellaneous drugs
- EPC transplantation—clinical experience
- How do EPCs improve neovascularization?
- Quo vadis?